BioPharma Intelligence Hub

FDA catalyst tracker, drug pipeline monitor & clinical trial data for 0 biotech companies. Free data from FDA, SEC EDGAR & ClinicalTrials.gov.

Upcoming Catalysts

No upcoming catalysts in the next 14 days. Data is being populated.

BioPharma Companies

Company data is being populated from SEC EDGAR. Check back shortly.

What is the BioPharma Intelligence Hub?

A free, data-driven platform that aggregates information from official US government sources to help you track pharmaceutical and biotechnology company developments. All data comes from public domain sources: the U.S. Food & Drug Administration (FDA), the Securities and Exchange Commission (SEC EDGAR), and the National Library of Medicine (ClinicalTrials.gov).

Catalyst Calendar

Track upcoming PDUFA dates, AdCom meetings, Phase 3 readouts, and other FDA regulatory events.

View Calendar →

Company Pipelines

Explore drug pipelines for 800+ biotech and pharma companies with trial status and regulatory timelines.

Browse Companies →

Clinical Trials

Monitor active clinical trials from ClinicalTrials.gov, organized by company, phase, and indication.

SEC Filings

FDA-related 8-K filings parsed and organized by company. Direct links to SEC EDGAR source documents.

Pipeline Development Grades

Companies are assessed using a transparent, published methodology based on objective data points. Grades reflect pipeline development progress, not investment merit.

A+ Strong pipeline: 18+ months cash runway, Phase 3+ programs, upcoming catalysts
A Above average: Adequate cash, advancing pipeline, identifiable catalysts
B Standard profile: Mixed signals, adequate cash but limited near-term catalysts
C Elevated risk factors: Limited cash runway, early-stage only, trial setbacks
D Significant concerns: Cash constraints, multiple trial failures, regulatory warnings

Read the full methodology →